Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02132832 · ClinicalTrials.gov registry record · Phase 2
Buspirone, Stress, and Attentional Bias to Marijuana Cues
A Phase 2 study, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT02132832 is a Phase 2 study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 45 participants.
The verdict
NCT02132832, a Phase 2 study, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
This project has two primary goals. The first goal is to further scientific understanding about marijuana abuse by examining two recognized factors in marijuana use and relapse: (1) stress/anxiety and (2) atypical reactivity to marijuana-related stimuli (e.g., attentional bias). The second goal is to attenuate the influence of stress/anxiety and attentional bias to marijuana stimuli via administration of buspirone. Buspirone is uniquely suited to this project because it has effects on neurotransmitter systems known to modulate both stress/anxiety and attentional bias.
Interventions
- DRUG Placebo
- DRUG Buspirone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2013-06 |
| Est. Completion | 2016-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02132832
The ClinicalTrials.gov registry entry for NCT02132832 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02132832 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02132832 about?
NCT02132832 is a clinical study titled "Buspirone, Stress, and Attentional Bias to Marijuana Cues". This project has two primary goals. The first goal is to further scientific understanding about marijuana abuse by examining two recognized factors in marijuana use and relapse: (1) stress/anxiety and (2) atypical reactivity to marijuana-related stimuli (e.g., attentional bias). The second goal is t...
What is the current status of trial NCT02132832?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2013-06. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02132832?
The interventions under investigation include: Placebo (DRUG), Buspirone (DRUG).
Who is sponsoring clinical trial NCT02132832?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.